RESOLUTIONS OF THE ANNUAL GENERAL MEETING 2018 OF EVOTEC AG

▸ *APPROVAL OF ALL AGENDA ITEMS WITH CLEAR MAJORITIES*
▸ *CONVERSION OF THE COMPANY INTO EUROPEAN COMPANY (SE) APPROVED*

Hamburg, Germany, 20 June 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting 2018 with the required majorities.

The Management Board presented the Company's progress in the year 2017 and provided the shareholders with an update and outlook regarding future developments of the Company in their presentation "Scientific Excellence meets Operational Excellence".

The strategy and its execution by the members of the Management Board and the Supervisory Board for the fiscal year 2017 were supported and approved. Furthermore, shareholders at the Annual General Meeting 2018 voted to support the conversion into a European Company with a majority of 99.96%. With this step, Evotec AG will be renamed Evotec SE with the registered seat and headquarters remaining in Hamburg, Germany, after finalising the mandatory negotiation process regarding the future arrangements for employee involvement. This conversion reflects the continuing international focus of the Evotec Group, which has grown considerably in recent years with subsidiaries in France, Germany, Italy, Switzerland, the United Kingdom and the USA.

The Annual General Meeting also approved the appointment of Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft, Hamburg, as the auditor for fiscal year 2018. At the ordinary Annual General Meeting 2018 of Evotec AG, 50.84% of the voting capital was present.

More information on the Company's Annual General Meeting including the voting results on all agenda items can be found on https://evotec.com/en/invest/annual-general-meeting.

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.

FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.